Poseida Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

Poseida Therapeutics

08/05/2023 13:05

* Poseida Therapeutics Inc  PSTX.OQ   PSTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 10
(estimated). 
    * The San Diego California-based  company is expected to
report  a
553.3% increase in revenue to $9.375 million from $1.44 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Poseida
Therapeutics Inc
is for a loss of 45 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $14​, above​ its last closing price
of $3.27. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.19       -0.22      -0.39     Missed  -73.3
 Sep. 30 2022  -0.63       -0.65      0.92      Beat    241
 Jun. 30 2022  -0.83       -0.76      -0.69     Beat    9.8​
 Mar. 31 2022  -0.65       -0.66      -0.93     Missed  -39.8
 ​​Dec.        -0.44       -0.35      0.02      Beat    105.8
 31 2021                                                
 Sep. 30 2021  -0.74       -0.74      -0.68     Beat    8.5​
 Jun. 30 2021  -0.63       -0.63      -0.74     Missed  -17.5
 Mar. 31 2021  -0.64       -0.63      -0.62     Beat    2.4
 This summary was machine generated May 8 at 12:05 GMT.  All
figures in US dollars  unless otherwise stated